Germany-based pharmaceutical group Boehringer Ingelheim has announced it has entered into a cooperation agreement with Cambridge, Massachusetts-based biotech Epizyme to develop two gene regulators for cancer, not clinically tested yet. Specifically, the candidate treatments are two enzymes within the helicase and histone acetyltransferase (HAT) families, both linked to gene dysregulation in tumors.
As part of the agreement, Epizyme will receive $15m in cash upon signature, plus an additional $5m to fund the first scientific activities. Additionally, the deal provides for payment of royalties on sales in the US up to a $280m maximum. This is the latest in a long series of research agreements signed by the Mainz-based group, which appears to be increasingly seeking development in the new precision medicine business.
(Source: Boehringer Ingelheim)